FY2025 Performance Highlights
- Revenue at ₹45,653m, grew 17.2% YoY
- Gross margin at ₹25,854m, grew 20.5% YoY
- EBITDA grew 36.8% YoY to ₹8,028m with EBITDA margin at 17.6%, grew 252bps YoY
- US revenue at $291m, grew 21.8% YoY
- Operational PAT at ₹3,447m, Grew 12x YoY
- Operational EPS at ₹37.5, Grew 12x YoY
Q4FY2025 Performance Highlights
- Revenue at ₹11,904m, grew 17.0% YoY
- Gross margin at ₹6,914m, grew 18.1% YoY
- EBITDA grew 22.0% YoY to ₹2,179m with EBITDA margin at 18.3%, grew 75bps YoY
- US revenue at $77m, grew 23.2% YoY
- Operational PAT at ₹1,130m, Grew 5x YoY
- Operational EPS at ₹12.3, Grew 5x YoY
Bangalore, India, May 22, 2025 – Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) today announced its consolidated financial results for the quarter (Q4FY25) and full year (FY25) ended March 31, 2025.
Financial Highlights (In ₹ m)
| Particulars | FY25 | FY24 | YoY | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
| Revenue | 45,653 | 38,945 | 17.2% | 11,904 | 10,178 | 17.0% | 11,537 | 3.2% |
| Gross Margin | 25,854 | 21,455 | 20.5% | 6,914 | 5,855 | 18.1% | 6,735 | 2.7% |
| Gross Margin % | 56.6% | 55.1% | 154bps | 58.1% | 57.5% | 56bps | 58.4% | -30bps |
| EBITDA | 8,028 | 5,868 | 36.8% | 2,179 | 1,786 | 22.0% | 2,103 | 3.6% |
| EBITDA % | 17.6% | 15.1% | 252bps | 18.3% | 17.5% | 75bps | 18.2% | 7bps |
| Operational PAT* | 3,447 | 279 | 12x | 1,130 | 242 | 5x | 925 | 22% |
| Operational EPS (₹) | 37.5 | 3.1 | 12x | 12.3 | 2.7 | 5x | 10 | 22% |
*Operational PAT = Reported PAT from continuing operations excluding exceptional items
Numbers presented have been adjusted to reflect the impact of the demerged Softgel business to OneSource
Arun Kumar, Founder & Non-Executive Chairperson, and Badree Komandur, MD & Group CEO, commented on the performance and said, “We are pleased to report a strong close to FY25, having successfully exceeded the outlook communicated across all key parameters. Our FY25 revenue grew by 17.2% YoY, outperforming our guidance of 12–15%, aided by strong US business performance. We also surpassed our EBITDA outlook, delivering ₹8,028m in FY25, reflecting enhanced operational efficiency and margin resilience post-demerger. We reduced Net debt by ₹5,128m, and our Net Debt-to-EBITDA ratio improved to 1.9x, well below the outlook given. The US business recorded $291m in revenue, representing 21.8% YoY growth and exceeding the outlook. This was propelled by new product launches, steady base business, and a strong commercial execution framework. We also delivered an operating PAT of ₹3,447m for FY25, reflecting continued focus on profitability. The Board has recommended a dividend of ₹4 per share for FY25, reflecting our strong financial performance.
As we look ahead, we remain focused on the disciplined execution of our business strategies, underpinned by strong governance and a deep commitment to ESG — all aimed at delivering superior business outcomes and creating long-term value for all stakeholders.”
About Strides
Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com.
For further information, please contact:
| Institutional Investors Vikesh Kumar Group CFO Email: investor-relations@strides.com Saurabh Ambaselkar Investor Relations – +91 99609 31220 Email: saurabh.ambaselkar@strides.com Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Corp. Office: Strides House, Bannerghatta Road, Bengaluru – 560076 | Corporate Communication Pallavi Panchmatia: +91 80 6784 0193 Email: pallavi.panchmatia@strides.com Janhavi Bellare: +91 93228 54508 Janhavi.bellare@adfactorspr.com Talal Syed: +91 99876 19679syed.talal@adfactorspr.com |
